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Abstract
Background: The synapse-associated protein 97 gene (SAP97) encodes a regulatory scaffold protein for the
localization of L-alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), kainate and N-methyl-D-
aspartate (NMDA) type glutamate receptors. We have recently demonstrated nominally significant associations
between SAP97 gene and schizophrenia among Japanese males. The present study aimed to replicate these
findings using an independent and larger sample.
Methods: We investigated seven SAP97 single nucleotide polymorphisms (SNPs) that displayed a significant
association with schizophrenia in our preceding study in an independent Japanese population consisting of a total
of 393 unrelated patients with schizophrenia (232 males and 161 females) and 393 unrelated control subjects (211
males and 182 females).
Results: The SNP rs9843659 showed a significant genotypic association with male patients in a recessive model (p
= 0.037). The analysis of the combined data from the current and prior studies also demonstrated a significant
association of this SNP (p = 0.0039). The meta-analysis for the allele frequency covering the two studies yielded an
odds ratio of 1.38.
Conclusions: The present study replicated the previously reported male-selective genetic association between the
SAP97 polymorphism and schizophrenia. These findings further support the possible involvement of the SAP97
gene variation in the susceptibility to schizophrenia in males and in the genetic basis for sex differences in the
disorder.
Keywords: Schizophrenia, genetic association, single nucleotide polymorphisms, synapse-associated protein, scaf-
folding protein, SAP97, gender selective, glutamate
Background
Schizophrenia is a serious psychiatric disorder with a
high prevalence of nearly 1% and a wide variety of men-
tal dysfunctions that are only partially improved by the
current antipsychotic drugs. It is well accepted that mul-
tiple susceptibility genes may be involved in the patho-
genesis of schizophrenia [1], and the search for such
genes has produced promising results [2]. To obtain a
further insight into the genetic factors, we have
investigated the possible association between schizo-
phrenia and the genes that are related to the impaired
N-methyl-D-aspartate (NMDA) receptor-mediated glu-
tamate neurotransmission and the development-depen-
dent onset of schizophrenia, because 1) NMDA receptor
antagonists, such as phencyclidine (PCP) and ketamine,
cause the psychotic symptoms indistinguishable from
those of schizophrenia [3,4], 2) the onset of schizophre-
nia and the above psychotomimetic effects typically
occur after puberty [5-9], and 3) in experimental ani-
mals, the adult type PCP- and dizocilpine (MK-801)-
induced abnormal behavior as a model of schizophrenic
symptoms is observed only after the weaning period
[10-12]. Recently, we have shown that the synapse-
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regulatory scaffold protein for the localization of L-
alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic
acid (AMPA), kainate and NMDA type glutamate recep-
tors [13], is upregulated in the adult but not in the
infant rat after PCP administration [14]. Moreover, we
have demonstrated nominally significant associations
between SAP97 single nucleotide polymorphisms (SNPs)
and schizophrenia among males [15]. In the present
study, we therefore aimed to replicate the prior genetic
association findings using an independent and larger
sample.
Methods
A total of 393 unrelated Japanese patients with schizo-
phrenia (232 males, 41.9 ± 11.4 years, and 161 females,
40.7 ± 12.3 years) and 393 unrelated Japanese control
subjects (211 males, 38.6 ± 10.9 years, and 182 females,
41.5 ± 12.9 years) were included in this study. All
patients were diagnosed by well-trained psychiatrists,
according to the Diagnostic and Statistical Manual of
Mental Disorders, fourth edition (DSM-IV) criteria. All
subjects resided in central Japan. The ethics committees
of the Tokyo Medical and Dental University and
National Center of Neurology and Psychiatry approved
the present study. The control subjects were recruited
through advertisements in free local information maga-
zines and by our website announcement. They were
interviewed using the Japanese version of the Mini-
International Neuropsychiatric Interview (M.I.N.I.)
[16,17] by a research psychiatrist, and those who had a
current or past history of psychiatric disorders were not
enrolled in the study. Participants were excluded if they
had prior medical histories of a central nervous system
disease or severe head injury, or if they met the criteria
for substance abuse or dependence, or mental retarda-
tion. This study was conducted in accordance with the
latest version of the Declaration of Helsinki.
We selected seven SNPs which displayed a significant
association with schizophrenia in the previous study
[15]. TaqMan SNP Genotyping Assay method (Applied
Biosystems, Foster City, CA, USA) was used to genotype
these SNPs as previously described [15]. The representa-
tive genotyping results were confirmed by the direct
sequence and TA cloning methods.
A statistical analysis was performed using the PLINK
1.07 software package http://pngu.mgh.harvard.edu/pur-
cell/plink/[18]. Deviation from the predicted Hardy-
Weinberg equilibrium (HWE) was evaluated by the chi-
square test. To compare the allele and genotype fre-
quencies between cases and controls, Fisher’s exact test
was performed. The analysis for genotype frequencies
was performed assuming dominant, recessive and co-
dominant effects for each polymorphism. In the
dominant model, both the major allele homozygote and
the heterozygote were combined. In the recessive model,
the variant was defined as only the major allele homozy-
gote. The co-dominant model compared the major allele
homozygote and heterozygote to the minor allele homo-
zygote. A meta-analysis was performed using the pack-
age (rmeta) for R-software http://www.r-project.org.
When there is no heterogeneity, the fixed-effects (Man-
tel-Haenszel) model was applied. Otherwise, the ran-
dom-effects (DerSimonian-Laird) model was used.
Results
The allele frequency and genotype distribution of each
SNP are summarized in Table 1. The genotype distribu-
tion of all the SNPs showed no significant deviations
from the HWE in the control or disease groups (p >
0.05).
Regarding male patients with schizophrenia, we
observed a genotypic association between schizophrenia
and SNP I-3 (rs9843659) in the recessive model (p =
0.037). Because there was a significant difference in the
mean age between patients and controls in the male
group (p = 0.0016), we performed a logistic regression
analysis in the recessive model to control the possible
confounding effect of age. The analysis yielded a statisti-
cal significance (p = 0.028). The SNP I-3 association in
the recessive model was also demonstrated in the com-
bined data from the current and prior studies (p =
0.0039) (Table 2). The p value remained statistically sig-
nificant after permutation testing (p = 0.0124, 10,000
permutations). SNP I-3 also showed an association in
the co-dominant model as well as an allelic association
(Table 2). The combined data further revealed allelic
and genotypic associations in SNP II-1 and II-8 (Table
2). The meta-analysis for the allele frequency covering
the current and prior studies yielded an odds ratio of
1.38 for SNP I-3, and 1.26 and 1.25 for SNP II-1 and II-
8, respectively, in the fixed-effects model (Table 2).
In the present study no significant case-control allele
or genotype differences was demonstrated when female
patients with schizophrenia were compared to control
females or when all subjects were analyzed (Table 1).
However, for the combined data from the current and
prior studies, we detected significant differences in the
allele and genotype frequencies in the recessive and co-
dominant models between all patients and controls for
SNP I-3, I-10, II-1 and II-8. Likewise, the meta-analyses
for the allele frequencies demonstrated statistically sig-
nificant odds ratios for these SNPs (Table 2).
Discussion
These findings add further support to our previous
report in that the SNP rs9843659 in the SAP97 gene is
genetically associated with male patients with
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Allele (1/2)
a Genotype Frequency (%) p value Allele Frequency (%) p value
Sex Group HWE 1/1 1/2 2/2 Dom Rec Codom 1 2 Allelic
SNP I-2 rs382579 T/C M CTL 1 130 (61.6) 71 (33.6) 10 (4.7) 0.675 0.561 0.744 331 (78.4) 91 (21.6) 0.470
SCZ 0.718 136 (58.6) 82 (35.3) 14 (6.0) 354 (76.3) 110 (23.7)
F CTL 1 116 (63.7) 59 (32.4) 7 (3.8) 0.776 0.910 0.939 291 (79.9) 73 (20.1) 0.848
SCZ 0.801 104 (64.6) 52 (32.3) 5 (3.1) 260 (80.7) 62 (19.3)
All CTL 1 246 (62.6) 130 (33.1) 17 (4.3) 0.865 0.714 0.884 622 (79.1) 164 (20.9) 0.667
SCZ 1 240 (61.1) 134 (34.1) 19 (4.8) 614 (78.1) 172 (21.9)
SNP I-3 rs9843659 T/C M CTL 0.083 86 (40.8) 88 (41.7) 37 (17.5) 0.545 0.037 0.101 260 (61.6) 162 (38.4) 0.076
SCZ 1 72 (31.0) 114 (49.1) 46 (19.8) 258 (55.6) 206 (44.4)
F CTL 0.755 70 (38.5) 84 (46.2) 28 (15.4) 0.769 1 0.946 224 (61.5) 140 (38.5) 0.814
SCZ 0.512 61 (37.9) 73 (45.3) 27 (16.8) 195 (60.6) 127 (39.4)
All CTL 0.137 156 (39.7) 172 (43.8) 65 (16.5) 0.512 0.104 0.230 484 (61.6) 302 (38.4) 0.123
SCZ 0.607 133 (33.8) 187 (47.6) 73 (18.6) 453 (57.6) 333 (42.4)
SNP I-4 rs2122824 G/T M CTL 1 126 (59.7) 75 (35.5) 10 (4.7) 0.538 0.501 0.650 327 (77.5) 95 (22.5) 0.430
SCZ 0.861 131 (56.5) 86 (37.1) 15 (6.5) 348 (75.0) 116 (25.0)
F CTL 1 113 (62.1) 61 (33.5) 8 (4.4) 0.583 1 0.834 287 (78.8) 77 (21.2) 0.851
SCZ 0.477 100 (62.1) 56 (34.8) 5 (3.1) 256 (79.5) 66 (20.5)
All CTL 0.883 239 (60.8) 136 (34.6) 18 (4.6) 0.868 0.611 0.846 614 (78.1) 172 (21.9) 0.587
SCZ 0.887 231 (58.8) 142 (36.1) 20 (5.1) 604 (76.8) 182 (23.2)
SNP I-5 rs7650753 G/T M CTL 1 126 (59.7) 75 (35.5) 10 (4.7) 0.419 0.63 0.629 327 (77.5) 95 (22.5) 0.430
SCZ 0.597 133 (57.3) 83 (35.8) 16 (6.9) 349 (75.2) 115 (24.8)
F CTL 1 112 (61.5) 62 (34.1) 8 (4.4) 0.583 1 0.851 286 (78.6) 78 (21.4) 0.779
SCZ 0.477 100 (62.1) 56 (34.8) 5 (3.1) 256 (79.5) 66 (20.5)
All CTL 0.883 238 (60.6) 137 (34.9) 18 (4.6) 0.743 0.771 0.855 613 (78.0) 173 (22.0) 0.673
SCZ 1 233 (59.3) 139 (35.4) 21 (5.3) 605 (77.0) 181 (23.0)
SNP I-10 rs7638423 A/G M CTL 0.123 98 (46.4) 84 (39.8) 29 (13.7) 0.892 0.504 0.773 280 (66.4) 142 (33.6) 0.572
SCZ 0.316 100 (43.1) 99 (42.7) 33 (14.2) 299 (64.4) 165 (35.6)
F CTL 0.610 86 (47.3) 76 (41.8) 20 (11.0) 0.866 0.231 0.431 248 (68.1) 116 (31.9) 0.294
SCZ 0.731 65 (40.4) 77 (47.8) 19 (11.8) 207 (64.3) 115 (35.7)
All CTL 0.137 184 (46.8) 160 (40.7) 49 (12.5) 0.831 0.196 0.394 528 (67.2) 258 (32.8) 0.264
SCZ 0.660 165 (42.0) 176 (44.8) 52 (13.2) 506 (64.4) 280 (35.6)
SNP II-1 rs6805920 C/A M CTL 0.166 98 (46.4) 85 (40.3) 28 (13.3) 0.784 0.390 0.675 281 (66.6) 141 (33.4) 0.438
SCZ 0.395 98 (42.2) 101 (43.5) 33 (14.2) 297 (64.0) 167 (36.0)
F CTL 0.610 86 (47.3) 76 (41.8) 20 (11.0) 0.737 0.231 0.440 248 (68.1) 116 (31.9) 0.259
SCZ 0.865 65 (40.4) 76 (47.2) 20 (12.4) 206 (64.0) 116 (36.0)
All CTL 0.170 184 (46.8) 161 (41.0) 48 (12.2) 0.670 0.151 0.324 529 (67.3) 257 (32.7) 0.184
SCZ 0.662 163 (41.5) 177 (45.0) 53 (13.5) 503 (64.0) 283 (36.0)
SNP II-8 rs4916461 A/C M CTL 0.080 104 (49.3) 80 (37.9) 27 (12.8) 0.679 0.505 0.736 288 (68.2) 134 (31.8) 0.572
SCZ 0.108 106 (45.7) 93 (40.1) 33 (14.2) 305 (65.7) 159 (34.3)
F CTL 0.491 88 (48.4) 74 (40.7) 20 (11.0) 1 0.278 0.490 250 (68.7) 114 (31.3) 0.415
SCZ 0.861 68 (42.2) 75 (46.6) 18 (11.2) 211 (65.5) 111 (34.5)
All CTL 0.079 192 (48.9) 154 (39.2) 47 (12.0) 0.746 0.224 0.453 538 (68.4) 248 (31.6) 0.260
SCZ 0.314 174 (44.3) 168 (42.7) 51 (13.0) 516 (65.6) 270 (34.4)
SNP, single-nucleotide polymorphism; HWE, Hardy-Weinberg equilibrium; M, male; F, female; All, male and female combined; CTL, control; SCZ, schizophrenia;
Dom, dominant model; Rec, Recessive model; Codom, Co-dominant model.
Bold values indicate significance level p < 0.05.
aAllele 1 and 2 represent the major and minor alleles of each SNP.
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for schizophrenia susceptibility in both studies. As repli-
cating results of a genetic association study in indepen-
dent samples is considered as a standard to demonstrate
the relevance of a candidate gene [19], the results of the
present study in conjunction with the previous study
strongly support the view that SAP97 i sar i s kg e n ef o r
male patients with schizophrenia.
In the most recent and largest genome-wide associa-
tion studies (GWAS), the tag SNP rs1392705 on chro-
mosome 3q29 closest to the SNP rs9843659 in the
SAP97 gene demonstrated a nominal genome-wide sig-
nificance (p = 8.45 × 10
-4) [20-22]. Another genome-
wide analysis of the copy-number variation (CNV)
found a statistically significant excess of deletions in
schizophrenia at 3q29 [23]. The telomeric breakpoint of
the minimal deletion in this study was 4.7 kb from the
transcriptional stop of the SAP97 gene. These findings
also implicate SAP97 as a candidate gene for schizo-
phrenia susceptibility.
The contributions of the rs9843659 polymorphism to
the development of schizophrenia remains unexplained
because 1) this SNP is found in the fourth large intron,
but not in the exons that encode the amino acid
sequences of the SAP97 protein including the functional
domains and motifs, and 2) as previously described,
bioinformatics tools we used failed to reveal any consen-
sus sequences in the intron part that may play a role in
the alternative promoter use or alternative splicing. The
rs9843659 polymorphism could cause certain modifica-
tions in the regulation of transcription or translation of
the SAP97 gene by an unidentified mechanism, for
instance, a change in its higher-order genome structure.
This type of a ‘silent’ SNP has indeed been observed to
alternate substrate specificity in the Multidrug Resis-
tance 1 (MDR1) gene [24].
From this view point, it is of interest to note that the
expressional changes of the SAP97 proteins have been
reported by two independent research groups in the
dorsolateral prefrontal cortex of postmortem schizo-
phrenic brains [25,26]. However, it is not totally
excluded that these results might be due to long-term
treatment with antipsychotic drugs [25,26] and another
research group failed to observe any significant altera-
tion in the SAP97 mRNA level in the cortical area [27].
Furthermore, animal experiments have revealed the
mutual interactions between SAP97 and the NMDA
receptor that is hypothesized to be dysfunctional in schi-
zophrenia brains. Thus, the SAP97 gene knockdown
reduced the surface expression of GluR1 and GluR2 and
inhibited both the AMPA and NMDA excitatory postsy-
naptic currents (EPSCs) [28], and the NMDA antago-
nists upregulated the SAP97 mRNA expression in the
cerebral cortex [14]. A more recent in vitro study using
transfection, viral infection, small interference RNA, and
antisense oligonucleotide techniques has demonstrated
in the rat prefrontal cortex a functional link of the
SAP97 proteins with the D4 type dopamine receptor
that is possibly aberrant in mental illnesses including
schizophrenia [29]. Taken together, the presumed dysre-
gulation of the SAP97 gene connected to the rs9843659
polymorphism could lead to the plausible NMDA recep-
tor deficits and/or abnormal dopamine neurotransmis-
sion in patients with schizophrenia.
The replicated male-selective genetic association of
SAP97 gene with schizophrenia appears to be in line
with the data indicating the sex-specific genetic associa-
tions with the disorder reported in several genes such as
Table 2 Combined analysis and meta-analysis from the
current and prior studies








M 0.179 0.409 0.214 0.404 1.19 (0.92-1.53)
F 0.494 1.000 0.475 0.751 1.11 (0.82-1.50)
All 0.107 0.418 0.115 0.260 1.17 (0.97-1.42)
SNP I-3
rs9843659
M 0.004 0.121 0.004 0.011 1.38 (1.11-1.71)
F 0.757 1.000 0.594 0.835 1.04 (0.82-1.33)
All 0.014 0.210 0.011 0.034 1.22 (1.04-1.44)
SNP I-4
rs2122824
M 0.089 0.409 0.105 0.222 1.24 (0.96-1.59)
F 0.657 0.527 0.427 0.436 1.07 (0.80-1.43)
All 0.085 0.698 0.064 0.165 1.18 (0.98-1.42)
SNP I-5
rs7650753
M 0.115 0.327 0.164 0.275 1.22 (0.95-1.57)
F 0.712 0.527 0.480 0.471 1.06 (0.79-1.42)
All 0.114 0.607 0.104 0.246 1.18 (0.98-1.42)
SNP I-10
rs7638423
M 0.078 0.497 0.053 0.142 1.23 (0.98-1.53)
F 0.303 0.783 0.100 0.150 1.06 (0.79-1.42)
All 0.038 0.727 0.010 0.028 1.20 (1.01-1.41)
SNP II-1
rs6805920
M 0.041 0.497 0.020 0.061 1.26 (1.01-1.58)
F 0.200 1.000 0.068 0.133 1.06 (0.79-1.42)
All 0.014 0.602 0.003 0.009 1.23 (1.04-1.46)
SNP II-8
rs4916461
M 0.046 0.420 0.037 0.104 1.25 (1.00-1.57)
F 0.269 0.888 0.120 0.215 1.16 (0.90-1.49)
All 0.021 0.532 0.008 0.027 1.22 (1.03-1.44)
SNP, single-nucleotide polymorphism; M, male; F, female; All, male and female
combined; Dom, dominant model; Rec, Recessive model; Codom, Co-
dominant model; CI, confidence interval.
Bold values indicate significance level p < 0.05.
aCombined analysis was performed on the combined data from the current
study and Sato et al.
bMeta-analysis was performed covering the current study and Sato et al. for
allele frequency
Uezato et al. Behavioral and Brain Functions 2012, 8:2
http://www.behavioralandbrainfunctions.com/content/8/1/2
Page 4 of 6Disrupted-In-Schizophrenia 1 (DISC1), reelin (RELN)
and D-amino acid oxidase (DAO)[ 3 0 - 3 2 ] .T h e s ep h e -
nomena might be related to the well-known gender dif-
ferences in schizophrenia [33] that, for instance, include
the clinical observations that male patients tend to exhi-
bit an earlier onset and severer course than female
patients, although the genetic basis of the sex-differ-
ences in schizophrenia remains unclear. Consequently,
the male-specific association seen in the SAP97 gene
could produce different influences on the putative dis-
turbed neurotransmission via the NMDA receptor
between male and female patients with schizophrenia.
Conclusions
In conclusion, the present findings have confirmed that
the glutamatergic transmission-linked and developmen-
tally-regulated schizophrenomimetic-responsive gene
SAP97 is associated with male patients with schizophre-
nia. As this unique association could provide a clue to
elucidating the pathological changes in the glutamate
system and their gender differences, further investiga-
tions are required in the larger and non-Japanese popu-
lations to extend its validity.
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